ArticleJournal of medical biochemistry2025
Effects of use of metformin or combination of metformin and pioglitazone on oxidative stress in type 2 diabetes mellitus.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Triglyceride-glucose index as a biochemical predictor of hypertension in patients with type 2 diabetes and prediabetes: Evidence from the NHANES database.Journal of medical biochemistry · 2026Article
- Correlation risk analysis of serum inflammatory factors and 25-hydroxyvitamin D in vascular lesions in type 2 diabetes patients.Journal of medical biochemistry · 2026Article
- Oxidative stress modulation in type 2 diabetes: Insights from metformin and pioglitazone therapy.Journal of medical biochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to examine how oxidative stress changes after treatment and its relationship with metabolic parameters in patients diagnosed with Type 2 Diabetes Mellitus treated with metformin alone or with a combination of metformin and pioglitazone. Methods: The study population consisted of a total of 60 patients, including the group diagnosed with Type 2 Diabetes Mellitus (T2DM) who received metformin 2x1000 mg (n=30) and the other group who received metformin with pioglitazone 2x15/1000 mg (n=30). Serum IMA (ischemia-modified albumin), TAS (total antioxidant status), TOS (total oxidant status) and thiol-disulphide homeostasis were measured before and after 12 weeks of treatment. Results: No significant change was detected in Native sulfhydryl (SH) and Total SH levels in both Metformin and combination groups. IMA levels increased significantly in both drug groups (p=0.03 and p=0.01, respectively). Although the TAS level increased in both groups, no significant change was detected. While the TOS and oxidative stress index (OSI) index decreased significantly in the combination group (p<0.001), the decrease in the metformin group was not significant. No significant difference was detected between Native SH, Total SH, Disulfide, IMA, TAS, TOS levels and OSI index changes of both drug groups. Conclusions: We found that the use of anti-diabetic drugs did not have a significant effect on oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.